How to you approach the risk/benefit discussion for hormone replacement therapy in perimenopausal women with significant vasomotor symptoms and borderline ASCVD risk?

Thank you for this question. It is a conversation of a bit complex nature to be had with the patient. Generally, I follow the steps of [1] educating the patient on the data on the use of HRT in setting of ASCVD in that HRT is indicated for treating moderate to severe perimenopausal symptoms up to 5 ...